Latest Health News

Centaurus Metals has achieved a key milestone with the granting of the Jaguar Nickel Sulphide Project mining lease and bolstered its copper-gold portfolio through the acquisition of the Rio Novo tenure, setting the stage for accelerated development and exploration in Brazil’s Carajás Mineral Province.

ASX Limited has updated its FY26 expense growth guidance upwards, reflecting increased investments in risk management and technology modernisation alongside ASIC Inquiry-related costs, while reporting strong unaudited 1H26 revenue growth.

Imricor Medical Systems has achieved multiple world-first procedures using real-time MRI guidance for cardiac ablation, advancing clinical trials and regulatory progress amid a strategic commercial expansion.

Emyria Limited has reported strong quarterly revenue growth driven by the expansion of its Empax clinic network across multiple Australian states, supported by a recent $8 million institutional placement to fund its national rollout and workforce expansion.

SenSen Networks has reported record cash receipts for the first half of FY26, driven by strong sales momentum in North America and Australia, alongside innovative product deployments.

Metro Mining delivered a record 6.2 million wet metric tonnes in 2025 shipments, supported by a strong cash position and nearing completion of legacy contracts. The company is poised for expanded production and improved margins in 2026 following operational and leadership changes.

Algorae Pharmaceuticals has advanced its AI drug discovery capabilities with the launch of AlgoraeOS v2 and secured key commercial partnerships, including a $3 million debt facility to support expansion in Australia and New Zealand.

Minerals 260 Limited has significantly expanded its Bullabulling Gold Project resource to 4.5 million ounces, nearly doubling its previous estimate, while advancing key development milestones ahead of a mid-2026 Pre-Feasibility Study completion.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Scalare Partners reported a remarkable 231% revenue increase in Q2 FY26, driven by full integration of recent acquisitions and new ecosystem initiatives. The company also turned operating cashflow positive, signalling strong momentum ahead.

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.

Ampol Limited reports a robust fourth quarter Lytton Refiner Margin of US$15.14 per barrel, underpinning a strong preliminary FY25 earnings update with an expected EBIT of approximately $945 million.